Castle Biosciences Statistics
Want to see CSTL full AI Analyst Report?
Castle Biosciences (CSTL) Stock Statistics & Valuation Metrics
Total Valuation
Castle Biosciences has a market cap or net worth of $1.00B. The enterprise value is $847.30M.
- Market Cap
- $1.00B
- Enterprise Value
- $847.30M
Share Statistics
Castle Biosciences has 30,818,290 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,818,290
- Owned by Insiders
- 1.80%
- Owned by Institutions
- 51.19%
Financial Efficiency
Castle Biosciences’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -6.85%.
- Return on Equity (ROE)
- -0.05
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- -6.85%
- Return on Capital Employed (ROCE)
- -0.08
- Revenue Per Employee
- 343.54K
- Profits Per Employee
- -24.11K
- Employee Count
- 1,002
- Asset Turnover
- 0.59
- Inventory Turnover
- 6.93
Valuation Ratios
The current PE Ratio of Castle Biosciences is -44.68. Castle Biosciences’s PEG ratio is 0.45.
- PE Ratio
- -44.68
- PS Ratio
- 2.78
- PB Ratio
- 2.20
- Price to FCF
- 265.02
- Price to Operating Cash Flow
- 26.50
- PEG Ratio
- 0.45
Income Statement
In the last 12 months, Castle Biosciences had revenue of 344.23M and earned -24.16M in profits. Earnings per share was -0.83.
- Revenue
- 344.23M
- Gross Profit
- 273.20M
- Operating Income
- -42.81M
- Pretax Income
- -29.51M
- Net Income
- -24.16M
- EBITDA
- 11.34M
- Earnings Per Share (EPS)
- -0.83
Cash Flow
In the last 12 months, operating cash flow was 39.74M and capital expenditures -35.78M, giving a free cash flow of 3.96M billion.
- Operating Cash Flow
- 39.74M
- Free Cash Flow
- 3.96M
- Free Cash Flow per Share
- 0.13
Dividends & Yields
Castle Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.38%
- Earnings Yield
- -2.19%
Stock Price Statistics
- Beta
- 0.62
- 52-Week Price Change
- -3.07%
- 50-Day Moving Average
- 34.24
- 200-Day Moving Average
- 28.10
- Relative Strength Index (RSI)
- 43.20
- Average Volume (3m)
- 376.98K
Important Dates
Castle Biosciences upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Castle Biosciences as a current ratio of 5.26, with Debt / Equity ratio of 7.84%
- Current Ratio
- 5.26
- Quick Ratio
- 5.11
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -7.04
- Interest Coverage Ratio
- -497.79
Taxes
In the past 12 months, Castle Biosciences has paid -5.36M in taxes.
- Income Tax
- -5.36M
- Effective Tax Rate
- 0.18
Enterprise Valuation
Castle Biosciences EV to EBITDA ratio is -164.41, with an EV/FCF ratio of 253.72.
- EV to Sales
- 2.67
- EV to EBITDA
- -164.41
- EV to Free Cash Flow
- 253.72
- EV to Operating Cash Flow
- 25.30
Balance Sheet
Castle Biosciences has $277.67M in cash and marketable securities with $36.57M in debt, giving a net cash position of $241.09M billion.
- Cash & Marketable Securities
- $277.67M
- Total Debt
- $36.57M
- Net Cash
- $241.09M
- Net Cash Per Share
- $7.82
- Tangible Book Value Per Share
- $12.63
Margins
Gross margin is 77.07%, with operating margin of -7.43%, and net profit margin of -6.10%.
- Gross Margin
- 77.07%
- Operating Margin
- -7.43%
- Pretax Margin
- -6.00%
- Net Profit Margin
- -6.10%
- EBITDA Margin
- -1.62%
- EBIT Margin
- -5.85%
Analyst Forecast
The average price target for Castle Biosciences is $48.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $48.29
- Price Target Upside
- 48.48% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 9.78%
- EPS Growth Forecast
- -81.20%
Scores
- Smart Score
- 9
- AI Score
- 63
